Darwin Advisors, LLC Cassava Sciences Inc Transaction History

Darwin Advisors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 18, 2022	BUY	$16.33 - $51.06 $102,764 - $321,320	6,293 New	6,293 $226,000
Q2 2022 Aug 03, 2022	SELL	$17.22 - $38.47 $108,365 - $242,091	-6,293 Closed	0 $0
Q1 2022 May 04, 2022	BUY	$32.6 - $53.05 $205,151 - $333,843	6,293 New	6,293 $234,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Darwin Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Darwin Advisors, LLC with notifications on news.